发明名称 |
Compositions for treatment of attention deficit hyperactivity disorder |
摘要 |
Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release. |
申请公布号 |
US9119809(B2) |
申请公布日期 |
2015.09.01 |
申请号 |
US201414255529 |
申请日期 |
2014.04.17 |
申请人 |
Ironshore Pharmaceuticals & Development, Inc. |
发明人 |
Lickrish David;Zhang Feng |
分类号 |
A61K31/137;A61K9/16;A61K9/22;A61K9/32;A61K9/52;A61K9/58;A61K9/50;A61K31/4458 |
主分类号 |
A61K31/137 |
代理机构 |
Vinson & Elkins LLP |
代理人 |
Vinson & Elkins LLP |
主权项 |
1. A solid, oral pharmaceutical composition comprising a plurality of particles, each comprising:
a core comprising an amphetamine or a pharmaceutical salt thereof and at least one pharmaceutically acceptable excipient; a sustained release layer enclosing the core; and a delayed release layer enclosing the sustained release layer, wherein when the composition is orally administered to a human subject, (i) there is a lag period of at least 6 hours during which the area under the curve of plasma concentration versus time (AUC0-6) of amphetamine or a pharmaceutical salt thereof is less than 10% of the total area under the curve at Tmax (AUC0-Tmax); and (ii) the time to Cmax (Tmax) is between 12 and 19 hours after administration. |
地址 |
Camana Bay KY US |